| Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test SD Lawn, P Mwaba, M Bates, A Piatek, H Alexander, BJ Marais, ... The Lancet infectious diseases 13 (4), 349-361, 2013 | 627 | 2013 |
| Antigen-processing machinery breakdown and tumor growth B Seliger, MJ Maeurer, S Ferrone Immunology today 21 (9), 455-464, 2000 | 626 | 2000 |
| Reducing mortality from 2019-nCoV: host-directed therapies should be an option A Zumla, DS Hui, EI Azhar, ZA Memish, M Maeurer The Lancet 395 (10224), e35-e36, 2020 | 594 | 2020 |
| Single-cell landscape of immunological responses in patients with COVID-19 JY Zhang, XM Wang, X Xing, Z Xu, C Zhang, JW Song, X Fan, P Xia, ... Nature immunology 21 (9), 1107-1118, 2020 | 583 | 2020 |
| New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects AI Zumla, SH Gillespie, M Hoelscher, PPJ Philips, ST Cole, I Abubakar, ... The Lancet infectious diseases 14 (4), 327-340, 2014 | 428 | 2014 |
| Immunological and inflammatory profiles in mild and severe cases of COVID-19 JW Song, C Zhang, X Fan, FP Meng, Z Xu, P Xia, WJ Cao, T Yang, XP Dai, ... Nature communications 11 (1), 3410, 2020 | 412 | 2020 |
| Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies S Tiberi, N du Plessis, G Walzl, MJ Vjecha, M Rao, F Ntoumi, S Mfinanga, ... The Lancet Infectious Diseases 18 (7), e183-e198, 2018 | 397 | 2018 |
| Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of … MJ Maeurer, SM Gollin, D Martin, W Swaney, J Bryant, C Castelli, ... The Journal of clinical investigation 98 (7), 1633-1641, 1996 | 393 | 1996 |
| Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts BJ Marais, K Lönnroth, SD Lawn, GB Migliori, P Mwaba, P Glaziou, ... The Lancet infectious diseases 13 (5), 436-448, 2013 | 392 | 2013 |
| Drug-resistant tuberculosis: time for visionary political leadership I Abubakar, M Zignol, D Falzon, M Raviglione, L Ditiu, S Masham, I Adetifa, ... The Lancet infectious diseases 13 (6), 529-539, 2013 | 375 | 2013 |
| The WHO Global Tuberculosis 2021 Report–not so good news and turning the tide back to End TB J Chakaya, E Petersen, R Nantanda, BN Mungai, GB Migliori, ... International Journal of Infectious Diseases 124, S26-S29, 2022 | 338 | 2022 |
| Host-directed therapies for infectious diseases: current status, recent progress, and future prospects A Zumla, M Rao, RS Wallis, SHE Kaufmann, R Rustomjee, P Mwaba, ... The Lancet Infectious Diseases 16 (4), e47-e63, 2016 | 325 | 2016 |
| Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers RS Wallis, M Maeurer, P Mwaba, J Chakaya, R Rustomjee, GB Migliori, ... The Lancet infectious diseases 16 (4), e34-e46, 2016 | 320 | 2016 |
| Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial F Meng, R Xu, S Wang, Z Xu, C Zhang, Y Li, T Yang, L Shi, J Fu, T Jiang, ... Signal transduction and targeted therapy 5 (1), 172, 2020 | 315 | 2020 |
| TAP off—tumors on B Seliger, MJ Maeurer, S Ferrone Immunology today 18 (6), 292-299, 1997 | 313 | 1997 |
| Tuberculosis biomarkers discovery: developments, needs, and challenges RS Wallis, P Kim, S Cole, D Hanna, BB Andrade, M Maeurer, M Schito, ... The Lancet infectious diseases 13 (4), 362-372, 2013 | 301 | 2013 |
| Diagnosing Helicobacter pylori in vivo by confocal laser endoscopy R Kiesslich, M Goetz, J Burg, M Stolte, E Siegel, MJ Maeurer, S Thomas, ... Gastroenterology 128 (7), 2119-2123, 2005 | 287 | 2005 |
| Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities R McNerney, M Maeurer, I Abubakar, B Marais, TD Mchugh, N Ford, ... Journal of Infectious Diseases 205 (suppl_2), S147-S158, 2012 | 279 | 2012 |
| Tuberculosis treatment and management—an update on treatment regimens, trials, new drugs, and adjunct therapies A Zumla, J Chakaya, R Centis, L D'Ambrosio, P Mwaba, M Bates, ... The Lancet Respiratory Medicine 3 (3), 220-234, 2015 | 272 | 2015 |
| Progress in tuberculosis vaccine development and host-directed therapies—a state of the art review SHE Kaufmann, C Lange, M Rao, KN Balaji, M Lotze, M Schito, AI Zumla, ... The Lancet Respiratory Medicine 2 (4), 301-320, 2014 | 264 | 2014 |
